{"id":186994,"date":"2026-08-07T12:46:09","date_gmt":"2026-08-07T07:16:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=186994"},"modified":"2026-08-07T12:46:11","modified_gmt":"2026-08-07T07:16:11","slug":"piramal-pharma-share-price-target-2027-2028-2030","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/","title":{"rendered":"Piramal Pharma Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>CMP Rs 171.66. FY26 EPS Rs N\/A; approximately 12% annual growth. Target 2027: Rs 245 (+43%). Target 2028: Rs 280. Target 2030: Rs 360 (+110%).<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/pplpharma\/piramal-pharma-ltd-share-price-today\">Piramal Pharma<\/a> at Rs 171.66 owns one of the very few dedicated ADC (antibody-drug-conjugate) manufacturing sites in the world at Grangemouth, Scotland, a scarce, high-margin capability riding the ADC cancer therapy boom. Global pharmaceutical companies including Pfizer, AstraZeneca, and others have been securing CDMO partnerships for ADC manufacturing, and Piramal&#8217;s Grangemouth facility gives it a structural position in this fast-growing niche. The Piramal Pharma share price target of Rs 245 for 2027, rising to Rs 360 by 2030, anchors to the street consensus while the company is still loss-making.<\/p>\n<p>The Piramal Pharma share price target of Rs 245 for 2027, rising to Rs 360 by 2030, reflects approximately 12% annual earnings growth with a forward multiple consistent with CDMO and Specialty Pharma peers. This article covers the Piramal Pharma share price target 2027, 2028, and 2030 based on FY26 financials and analyst estimates as of August 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=piramal-pharma-tgt\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Piramal_Pharma_Company_Overview\" title=\"Piramal Pharma Company Overview\">Piramal Pharma Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Why_Is_the_Piramal_Pharma_Share_Price_Target_Set_at_Rs_245_for_2027\" title=\"Why Is the Piramal Pharma Share Price Target Set at Rs 245 for 2027\">Why Is the Piramal Pharma Share Price Target Set at Rs 245 for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#ADC_Manufacturing_at_Grangemouth_Is_a_Globally_Scarce_High-Margin_Capability\" title=\"ADC Manufacturing at Grangemouth Is a Globally Scarce High-Margin Capability\">ADC Manufacturing at Grangemouth Is a Globally Scarce High-Margin Capability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#CDMO_Business_Provides_Revenue_Visibility_Through_Long-Term_Manufacturing_Contracts\" title=\"CDMO Business Provides Revenue Visibility Through Long-Term Manufacturing Contracts\">CDMO Business Provides Revenue Visibility Through Long-Term Manufacturing Contracts<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#India_API_and_CRAMS_Business_Provides_a_Stable_Domestic_Revenue_Base\" title=\"India API and CRAMS Business Provides a Stable Domestic Revenue Base\">India API and CRAMS Business Provides a Stable Domestic Revenue Base<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Complex_Hospital_Generics_Segment_Has_High_Regulatory_Barrier_to_Entry\" title=\"Complex Hospital Generics Segment Has High Regulatory Barrier to Entry\">Complex Hospital Generics Segment Has High Regulatory Barrier to Entry<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Path_to_Profitability_by_FY27_to_FY28_Is_the_Key_Milestone_for_Re-Rating\" title=\"Path to Profitability by FY27 to FY28 Is the Key Milestone for Re-Rating\">Path to Profitability by FY27 to FY28 Is the Key Milestone for Re-Rating<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Piramal_Pharma_Share_Price_Targets_2027_2028_and_2030\" title=\"Piramal Pharma Share Price Targets 2027, 2028 and 2030\">Piramal Pharma Share Price Targets 2027, 2028 and 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Piramal_Pharma_Share_Price_Target_2027_Rs_245\" title=\"Piramal Pharma Share Price Target 2027: Rs 245\">Piramal Pharma Share Price Target 2027: Rs 245<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Piramal_Pharma_Share_Price_Target_2028_Rs_280\" title=\"Piramal Pharma Share Price Target 2028: Rs 280\">Piramal Pharma Share Price Target 2028: Rs 280<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Piramal_Pharma_Share_Price_Target_2030_Rs_360\" title=\"Piramal Pharma Share Price Target 2030: Rs 360\">Piramal Pharma Share Price Target 2030: Rs 360<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Bull_Case_and_Bear_Case_for_the_Piramal_Pharma_Share_Price_Target_2030\" title=\"Bull Case and Bear Case for the Piramal Pharma Share Price Target 2030\">Bull Case and Bear Case for the Piramal Pharma Share Price Target 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Bull_Case_Rs_461\" title=\"Bull Case: Rs 461\">Bull Case: Rs 461<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Bear_Case_Rs_274\" title=\"Bear Case: Rs 274\">Bear Case: Rs 274<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Key_Risks_to_the_Piramal_Pharma_Share_Price_Target\" title=\"Key Risks to the Piramal Pharma Share Price Target\">Key Risks to the Piramal Pharma Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#USFDA_Inspection_and_Compliance_Risk\" title=\"USFDA Inspection and Compliance Risk\">USFDA Inspection and Compliance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Currency_Risk_on_Export_Revenue\" title=\"Currency Risk on Export Revenue\">Currency Risk on Export Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Pricing_Pressure_in_Regulated_Generic_Markets\" title=\"Pricing Pressure in Regulated Generic Markets\">Pricing Pressure in Regulated Generic Markets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Clinical_Trial_and_Pipeline_Risk\" title=\"Clinical Trial and Pipeline Risk\">Clinical Trial and Pipeline Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#How_to_Invest_in_Piramal_Pharma\" title=\"How to Invest in Piramal Pharma\">How to Invest in Piramal Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Frequently_Asked_Questions_on_Piramal_Pharma_Share_Price_Target_2027_2028_and_2030\" title=\"Frequently Asked Questions on Piramal Pharma Share Price Target 2027 2028 and 2030\">Frequently Asked Questions on Piramal Pharma Share Price Target 2027 2028 and 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#What_is_the_Piramal_Pharma_share_price_target_for_2027\" title=\"What is the Piramal Pharma share price target for 2027?\">What is the Piramal Pharma share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#What_is_the_Piramal_Pharma_share_price_target_for_2030\" title=\"What is the Piramal Pharma share price target for 2030?\">What is the Piramal Pharma share price target for 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#Is_Piramal_Pharma_a_good_long-term_investment\" title=\"Is Piramal Pharma a good long-term investment?\">Is Piramal Pharma a good long-term investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#What_do_most_investors_miss_about_Piramal_Pharma\" title=\"What do most investors miss about Piramal Pharma?\">What do most investors miss about Piramal Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#What_is_the_bull_case_for_the_Piramal_Pharma_share_price_target_2030\" title=\"What is the bull case for the Piramal Pharma share price target 2030?\">What is the bull case for the Piramal Pharma share price target 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#What_are_the_main_risks_to_the_Piramal_Pharma_share_price_target\" title=\"What are the main risks to the Piramal Pharma share price target?\">What are the main risks to the Piramal Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#What_is_Piramal_Pharmas_52-week_high_and_low_share_price\" title=\"What is Piramal Pharma&#8217;s 52-week high and low share price?\">What is Piramal Pharma&#8217;s 52-week high and low share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2027-2028-2030\/#How_can_I_buy_Piramal_Pharma_shares\" title=\"How can I buy Piramal Pharma shares?\">How can I buy Piramal Pharma shares?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Company_Overview\"><\/span><strong>Piramal Pharma Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Metric<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Details<\/th>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">NSE Ticker<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\"><a href=\"https:\/\/univest.in\/stocks\/pplpharma\/piramal-pharma-ltd-share-price-today\">PPLPHARMA<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Sector<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">CDMO and Specialty Pharma<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">CMP (05 Aug 2026)<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 171.66<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">52-Week High<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 250<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">52-Week Low<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 115<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Market Cap<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 23,599 Cr<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">FY26 EPS<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">See rationale<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Promoter Holding<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">35%<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">12M Consensus<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">\u20b9244 (+42%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Piramal Pharma Share Price Target 2027<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 245 (+43%)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Piramal Pharma Share Price Target 2028<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 280 (+63%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Piramal Pharma Share Price Target 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 360 (+110%)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 461<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 274<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"border-left: 4px solid #e67e22; background: #FEF9F0; padding: 10px 16px;\"><strong>What most investors miss:<\/strong> Piramal Pharma owns one of the very few dedicated antibody-drug-conjugate (ADC) manufacturing sites globally at Grangemouth, Scotland. ADCs are the fastest-growing oncology drug class globally, and manufacturing capacity is severely constrained. Piramal&#8217;s early-mover position in ADC CDMO gives it a strategic advantage that should convert into multi-year high-margin contracts as pharma companies scale up their ADC pipelines.<\/p>\n<p>Since the company is still loss-making, we&#8217;ve anchored to the \u20b9244 street target and rolled it forward assuming approximately14% underlying growth. . The share price targets of Rs 245 for 2027, Rs 280 for 2028, and Rs 360 for 2030 are derived from this earnings trajectory and peer multiples.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Piramal_Pharma_Share_Price_Target_Set_at_Rs_245_for_2027\"><\/span><strong>Why Is the Piramal Pharma Share Price Target Set at Rs 245 for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"ADC_Manufacturing_at_Grangemouth_Is_a_Globally_Scarce_High-Margin_Capability\"><\/span><strong>ADC Manufacturing at Grangemouth Is a Globally Scarce High-Margin Capability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the foundational driver of the Piramal Pharma share price target of Rs 245 for 2027 and Rs 360 by 2030. Since the company is still loss-making, we&#8217;ve anchored to the \u20b9244 street target and rolled it forward assuming approximately14% underlying growth. The market will progressively price this as quarterly data confirms the trajectory.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"CDMO_Business_Provides_Revenue_Visibility_Through_Long-Term_Manufacturing_Contracts\"><\/span><strong>CDMO Business Provides Revenue Visibility Through Long-Term Manufacturing Contracts<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Investors analysing the Piramal Pharma share price target should track this dimension quarterly, as it provides the clearest signal of whether the compounding thesis is on track. Evidence of sustained improvement in this area is the primary re-rating catalyst for the Piramal Pharma share price target 2028 of Rs 262.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"India_API_and_CRAMS_Business_Provides_a_Stable_Domestic_Revenue_Base\"><\/span><strong>India API and CRAMS Business Provides a Stable Domestic Revenue Base<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This structural factor is often underweighted in standard Piramal Pharma share price target analyses, which focus on trailing earnings multiples rather than the competitive positioning embedded in the long-term franchise value. Its persistence through economic cycles is what differentiates the Piramal Pharma share price target 2030 case from a short-term trading call.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Complex_Hospital_Generics_Segment_Has_High_Regulatory_Barrier_to_Entry\"><\/span><strong>Complex Hospital Generics Segment Has High Regulatory Barrier to Entry<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For the Piramal Pharma share price target of Rs 360 to materialise by 2030, this factor needs to remain intact and compound over 4 years. Quarterly updates on this metric provide the earliest warning signal of any deviation from the Piramal Pharma share price target base case assumptions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Path_to_Profitability_by_FY27_to_FY28_Is_the_Key_Milestone_for_Re-Rating\"><\/span><strong>Path to Profitability by FY27 to FY28 Is the Key Milestone for Re-Rating<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As India&#8217;s economy compounds through 2027 to 2030, this factor provides an additional secular tailwind that is layered on top of the Piramal Pharma-specific earnings growth already embedded in the Rs 245 target for 2027 and the Rs 360 target for 2030.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Share_Price_Targets_2027_2028_and_2030\"><\/span><strong>Piramal Pharma Share Price Targets 2027, 2028 and 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Share_Price_Target_2027_Rs_245\"><\/span><strong>Piramal Pharma Share Price Target 2027: Rs 245<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Piramal Pharma share price target 2027 is Rs 245, representing approximately 43 percent upside from CMP Rs 171.66. Since the company is still loss-making, we&#8217;ve anchored to the \u20b9244 street target and rolled it forward assuming approximately14% underlying growth.. By 2027, the key catalyst for achieving this level is validation of the earnings trajectory through 2 consecutive quarters of on-target performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Share_Price_Target_2028_Rs_280\"><\/span><strong>Piramal Pharma Share Price Target 2028: Rs 280<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Piramal Pharma share price target 2028 is Rs 280, implying approximately 63 percent upside from CMP. By 2028, Piramal Pharma should have demonstrated through a full earnings cycle that the approximately 12% growth assumption is sustainable, supporting a re-rating toward the Piramal Pharma share price target 2028 level at a forward multiple consistent with sector peers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Share_Price_Target_2030_Rs_360\"><\/span><strong>Piramal Pharma Share Price Target 2030: Rs 360<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Piramal Pharma share price target 2030 is Rs 360, implying approximately 110 percent upside from CMP and a 4-year CAGR of approximately 20% from current levels. By 2030, Piramal Pharma should be a mature, well-understood franchise with a track record of consistent compounding that justifies the target multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_for_the_Piramal_Pharma_Share_Price_Target_2030\"><\/span><strong>Bull Case and Bear Case for the Piramal Pharma Share Price Target 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_461\"><\/span><strong>Bull Case: Rs 461<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Piramal Pharma share price target of Rs 461 by 2030: Rs 460 by 2030, if the ADC manufacturing contracts scale materially and Grangemouth is expanded, contributing Rs 800 to 1,000 crore annually to EBITDA by FY31, driving a CDMO premium re-rating.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Rs_274\"><\/span><strong>Bear Case: Rs 274<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bear case Piramal Pharma share price target of Rs 274 by 2030: Rs 280 by 2030, if ADC demand concentration with a few large pharma companies creates client concentration risk, Grangemouth faces operational challenges, and the path to profitability extends beyond FY29.<\/p>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Scenario<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Target by 2030<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Return<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Key Assumption<\/th>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 461<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+169%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Upside scenario with favourable execution and sector conditions<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Base Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 360<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+110%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">approximately 12% EPS CAGR; peer-multiple sustained through FY31<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 274<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+60%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Downside scenario with adverse execution or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Piramal_Pharma_Share_Price_Target\"><\/span><strong>Key Risks to the Piramal Pharma Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"USFDA_Inspection_and_Compliance_Risk\"><\/span><strong>USFDA Inspection and Compliance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any USFDA warning letter or import alert on Piramal Pharma&#8217;s manufacturing facilities would delay product launches and revenue recognition, directly reducing the earnings trajectory behind the Piramal Pharma share price target. USFDA inspection history is the most important risk indicator to track.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Currency_Risk_on_Export_Revenue\"><\/span><strong>Currency Risk on Export Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Piramal Pharma&#8217;s international revenue is primarily in US dollars and euros. Any significant INR appreciation against these currencies would reduce the INR value of reported revenues and EPS, compressing the Piramal Pharma share price target earnings assumptions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Pricing_Pressure_in_Regulated_Generic_Markets\"><\/span><strong>Pricing Pressure in Regulated Generic Markets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the US and EU generic markets, pricing erosion from competition intensifies as multiple players receive approvals for the same molecule. Any acceleration in generic pricing erosion in Piramal Pharma&#8217;s key export products would compress the Piramal Pharma share price target revenue base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Clinical_Trial_and_Pipeline_Risk\"><\/span><strong>Clinical Trial and Pipeline Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any setback in Piramal Pharma&#8217;s clinical trial results or regulatory approvals for pipeline products would delay the revenue ramp from specialty or novel products embedded in the Piramal Pharma share price target 2028 and 2030 assumptions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Piramal_Pharma\"><\/span><strong>How to Invest in Piramal Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use the Univest Screener to track Piramal Pharma&#8217;s key financial metrics including EPS growth, margin trends, and analyst upgrades or downgrades in real time. To purchase shares, open a demat account with any SEBI-registered broker and search for NSE ticker PPLPHARMA. Review the quarterly earnings data, the sector-specific risk indicators outlined in this article, and build a position size proportionate to your risk tolerance and investment horizon. Monitor each quarter for the key variables most likely to move the Piramal Pharma share price target. Consult a SEBI-registered financial advisor before making any investment decision.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to Track This Stock Live<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Piramal Pharma share price target of Rs 245 for 2027, Rs 280 for 2028, and Rs 360 for 2030 reflects approximately 12% annual earnings compounding and a forward multiple consistent with CDMO and Specialty Pharma peers. The key drivers and risks are outlined above. Piramal Pharma owns one of the very few dedicated antibody-drug-conjugate (ADC) manufacturing sites globally at Grangemouth, Scotland. ADCs are the fa. For investors with a 3 to 4 year horizon and a tolerance for CDMO and Specialty Pharma-specific risk, the current CMP of Rs 171.66 offers a starting point for building a position aligned to the Piramal Pharma share price target 2030 thesis. Always verify data at NSE and BSE before investing.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-portfolio\/id1479183301\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=in.univest.app\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Piramal Pharma share price live and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Piramal_Pharma_Share_Price_Target_2027_2028_and_2030\"><\/span><strong>Frequently Asked Questions on Piramal Pharma Share Price Target 2027 2028 and 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_share_price_target_for_2027\"><\/span><strong>What is the Piramal Pharma share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Piramal Pharma share price target for 2027 is Rs 245, representing approximately 43 percent upside from CMP Rs 171.66 as of August 2026. Please verify all data with the official NSE website before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_share_price_target_for_2030\"><\/span><strong>What is the Piramal Pharma share price target for 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Piramal Pharma share price target for 2030 is Rs 360, implying approximately 110 percent upside from CMP Rs 171.66. This is based on analyst estimates and is not a guaranteed return. Always verify current data at NSE India before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Piramal_Pharma_a_good_long-term_investment\"><\/span><strong>Is Piramal Pharma a good long-term investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Piramal Pharma has a defined analyst consensus that projects earnings compounding through FY31 based on sector-specific growth drivers outlined in this article. Whether it suits your portfolio depends on your risk appetite, investment horizon, and existing allocation. Consult a SEBI-registered financial advisor for personalised guidance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_do_most_investors_miss_about_Piramal_Pharma\"><\/span><strong>What do most investors miss about Piramal Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Piramal Pharma owns one of the very few dedicated antibody-drug-conjugate (ADC) manufacturing sites in the world (Grangemouth, Scotland) &#8211; a scarce, high-margin capability riding the ADC boom (Pfizer-Seagen, AZ-Daiichi deals) that the market underappreciates while the stock optically looks loss-maki<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_bull_case_for_the_Piramal_Pharma_share_price_target_2030\"><\/span><strong>What is the bull case for the Piramal Pharma share price target 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case Piramal Pharma share price target for 2030 is Rs 461. This requires better-than-base-case execution on the key growth drivers specific to Piramal Pharma&#8217;s sector, as described in this article. These are analyst projections, not guaranteed returns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Piramal_Pharma_share_price_target\"><\/span><strong>What are the main risks to the Piramal Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The key risks to the Piramal Pharma share price target include sector-specific headwinds such as credit cycles (for financial companies), regulatory changes, competitive pressure, and macroeconomic slowdown. Please review the risks section of this article for a full breakdown of the four most material risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Piramal_Pharmas_52-week_high_and_low_share_price\"><\/span><strong>What is Piramal Pharma&#8217;s 52-week high and low share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of August 2026, Piramal Pharma&#8217;s 52-week high is approximately Rs 250 and the 52-week low is approximately Rs 115. The CMP of Rs 171.66 sits between these levels. Always verify the latest 52-week data at NSE India or BSE before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_can_I_buy_Piramal_Pharma_shares\"><\/span><strong>How can I buy Piramal Pharma shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can buy Piramal Pharma shares through any SEBI-registered broker by searching for the NSE ticker PPLPHARMA. Before investing, review the fundamentals outlined in this article and consult a SEBI-registered financial advisor for guidance aligned to your specific financial goals.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma share price target 2027 is Rs 245 (+43%), 2028 is Rs 280, and 2030 is Rs 360 (+110%). CDMO and Specialty Pharma stock. Full long term analyst for<\/p>\n","protected":false},"author":36,"featured_media":186993,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-186994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["186993"],"_edit_lock":["1786086974:36"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["78"],"rank_math_title":["Piramal Pharma Share Price Target 2027 2028 and 2030"],"rank_math_description":["Piramal Pharma share price target 2027 is Rs 245 (+43%), 2028 is Rs 280, and 2030 is Rs 360 (+110%). CDMO and Specialty Pharma stock. Full long term analyst for"],"rank_math_focus_keyword":["Piramal Pharma share price target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_wp_old_date":["2026-08-05"],"_edit_last":["36"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["34959"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/piramal-pharma-share-price-target-2027-2028-2030.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/186994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=186994"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/186994\/revisions"}],"predecessor-version":[{"id":190674,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/186994\/revisions\/190674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/186993"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=186994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=186994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=186994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}